Netherlands· NL-bd2019c3c41d
ZTALMY 50 mg/ml orale suspensie
A ganaxolone product containing ganaxolon, registered in Netherlands by Immedica Pharma AB. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Ganaxolone is registered in 9 of 19 countries.
Countries holding a registration under ATC N03AX27 (ganaxolone), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Ganaxolone · ATC N03AX27
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- GANAXOLON
- Manufacturer
- Immedica Pharma AB
- Country
- Netherlands (NL)
- ATC code
- N03AX27
- ATC class
- Ganaxolone
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1743
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ganaxolone in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZTALMYImmedica Pharma AB, Stockholm
- SpainZTALMY 50 MG/ML SUSPENSION ORALImmedica Pharma Ab
- FinlandZTALMYImmedica Pharma AB
- IrelandZTALMY 50 mg/mL oral suspensionMarinus Pharmaceuticals Emerald Limited
- IcelandZtalmyImmedica Pharma AB
- PolandZtalmyMarinus Pharmaceuticals Emerald Limited
- SwedenZTALMY 50 mg/ml Oral suspensionImmedica Pharma AB
- BelgiumZtalmy 50 mg/mlMarinus Pharmaceuticals Emerald
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ztalmy
- Liechtenstein · Ztalmy
- Norway · Ztalmy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da419b55-1e83-4b9e-83b5-d03d7c1ae49e GET /v1/drugs/da419b55-1e83-4b9e-83b5-d03d7c1ae49e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Suspensie voor oraal gebruik",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ztalmy-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Ganaxolone",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129092",
"excipients": [
"BENZOËZUUR (E 210)",
"BENZYLALCOHOL (E 1519)",
"CITROENZUUR 0-WATER (E 330)",
"GLYCEROLMONOSTEARAAT (E 471)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"KERSENSMAAKSTOF",
"MACROGOLSTEARAAT, TYPE I",
"METHYLCELLULOSE (E 461)",
"METHYLPARAHYDROXYBENZOAAT (E 218)",
"NATRIUMBENZOAAT (E 211)",
"NATRIUMLAURILSULFAAT",
"POLYSORBAAT 65 (E 436)",
"POLYVINYLALCOHOL (E 1203)",
"PROPYLEENGLYCOL (E 1520)",
"PROPYLPARAHYDROXYBENZOAAT",
"SIMETICON",
"SIMETICON EMULSIE",
"SORBINEZUUR (E 200)",
"SUCRALOSE (E 955)",
"WATER, GEZUIVERD",
"WATER, GEZUIVERD",
"XANTHAANGOM (E 415)"
],
"substances": [
"GANAXOLON"
],
"leaflet_url": null,
"authorised_at": "2023/07/26",
"procedure_number": "EMEA/H/C/005825",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1743",
"additional_monitoring": "Y"
}See everything about ganaxolone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.